Report Suggests That Use of Psychedelics May Improve Color Blindness

A recent study conducted proposes that psychedelic substances may reduce color blindness symptoms. The findings, which were reported in “Drug Sciences, Policy and Law,” discuss more than 20 anecdotal reports that describe how color blindness was improved after participants ingested drugs such as psilocybin and LSD.

Historical and anecdotal reports have maintained for a while that psychedelic substances could adjust color vision. The researchers who conducted the study note that hurdles to carrying out more research on psychedelics have impeded further research on this.

In prior studies, JEC Anthony and his colleagues accepted submissions from individuals who recorded changes in symptoms of their color blindness after they’d consumed psychedelics. This led the researchers to look into these experiences and find out whether they were common, which prompted them to conduct an analysis of responses to the Global Drugs Survey of 2017.

The survey was made up of many questions, including one that asked respondents who were color blind if their color vision was altered after they had used a psychedelic substance. The question received more than 40 responses, which the researchers classified. Almost half of those who responded to this question reported that they experienced no improvements to their symptoms after they’d consumed a psychedelic substance, with the remainder revealing that they did.

The researchers noted that while other drugs were cited, psilocybin and LSD were mentioned the most with regard to improving the symptoms of color blindness. While there weren’t many reports to examine, the researchers stated that those given were enough to conclude that the recreational use of psychedelics could lessen color blindness in some users.

In addition to this, there were also indications that these improvements could be felt even after the intoxication period had elapsed. Almost 40% of the individuals who experienced vision changes revealed that these changes lasted anywhere between three days to a few years after they’d consumed the drug.

While the reason why these substances can influence color blindness is yet to be determined, the researchers note that it may be linked to a serotonin receptor known as 5-HT2A. They explained that psychedelic substances such as psilocybin and LSD were known to activate that receptor, which could permit the formation of new connections in cortical regions and improve neural plasticity.

The authors of the research admit that there were considerable limitations to their study and findings. For instance, the survey responses weren’t comprehensive enough to allow the researchers to differentiate between the various types of color blindness.

It appears that psychedelics, whose role in mental health is becoming all too apparent, may have more to offer with regard to improving human health. It remains to be seen what companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) will bring to market once their ongoing R&D yields medicinal formulations that are approved by regulators.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050